Key points from article :
Insilico Medicine closes $255 million to progress into human trials, initiate new programmes for novel and difficult targets, and develop its AI and drug discovery capabilities.
Collaborated with Teva Pharmaceutical Industries Ltd to identify novel therapeutic targets in various diseases.
The first case of AI identifying a novel target for a pulmonary disease, generating novel molecules, and completing the preclinical experiments in under 18 months.
Developed PandaOmics AI-powered novel target discovery engine, Chemistry42, InClinico.
“The AI technologies are...delivering valuable and absolutely novel therapeutic assets with high probability of clinical success,” - Alex Zhavoronkov, CEO of Insilico Medicine.
Technologies available for licensing for the pharmaceutical and biotechnology companies.
7 out of the top 30 pharmaceutical companies deployed its software.
Started a drug discovery team and platform in China.
More information on Insilico and its research will be available at ARDD.
